Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M.

J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14.

2.

Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy.

Mousset CM, Hobo W, Ji Y, Fredrix H, De Giorgi V, Allison RD, Kester MGD, Falkenburg JHF, Schaap NPM, Jansen JH, Gattinoni L, Dolstra H, van der Waart AB.

Oncoimmunology. 2018 Aug 6;7(10):e1488565. doi: 10.1080/2162402X.2018.1488565. eCollection 2018.

3.

Identification of non-mutated neoantigens presented by TAP-deficient tumors.

Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T.

J Exp Med. 2018 Sep 3;215(9):2325-2337. doi: 10.1084/jem.20180577. Epub 2018 Aug 16.

4.

The simultaneous isolation of multiple high and low frequent T-cell populations from donor peripheral blood mononuclear cells using the major histocompatibility complex I-Streptamer isolation technology.

Roex MCJ, Hageman L, Heemskerk MT, Veld SAJ, van Liempt E, Kester MGD, Germeroth L, Stemberger C, Falkenburg JHF, Jedema I.

Cytotherapy. 2018 Apr;20(4):543-555. doi: 10.1016/j.jcyt.2018.01.008. Epub 2018 Feb 12.

PMID:
29449085
5.

Specific T Cell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface.

Bijen HM, Hassan C, Kester MGD, Janssen GMC, Hombrink P, de Ru AH, Drijfhout JW, Meiring HD, de Jong AP, Falkenburg JHF, Jimenez CR, Heemskerk MHM, van Veelen PA.

Proteomics. 2018 Jun;18(12):e1700250. doi: 10.1002/pmic.201700250. Epub 2018 Feb 23.

PMID:
29251415
6.

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.

Franssen LE, Roeven MWH, Hobo W, Doorn R, Oostvogels R, Falkenburg JHF, van de Donk NW, Kester MGD, Fredrix H, Westinga K, Slaper-Cortenbach I, Spierings E, Kersten MJ, Dolstra H, Mutis T, Schaap N, Lokhorst HM.

Bone Marrow Transplant. 2017 Oct;52(10):1378-1383. doi: 10.1038/bmt.2017.118. Epub 2017 Jun 5.

PMID:
28581468
7.

Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo.

Thordardottir S, Schaap N, Louer E, Kester MG, Falkenburg JH, Jansen J, Radstake TR, Hobo W, Dolstra H.

Oncoimmunology. 2017 Feb 6;6(3):e1285991. doi: 10.1080/2162402X.2017.1285991. eCollection 2017.

8.

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.

Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.

Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4.

9.

Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.

Jahn L, van der Steen DM, Hagedoorn RS, Hombrink P, Kester MG, Schoonakker MP, de Ridder D, van Veelen PA, Falkenburg JH, Heemskerk MH.

Oncotarget. 2016 Nov 22;7(47):77021-77037. doi: 10.18632/oncotarget.12778.

10.

A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.

Jahn L, Hagedoorn RS, van der Steen DM, Hombrink P, Kester MG, Schoonakker MP, de Ridder D, van Veelen PA, Falkenburg JH, Heemskerk MH.

Oncotarget. 2016 Nov 1;7(44):71536-71547. doi: 10.18632/oncotarget.12247.

11.

Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2.

Pont MJ, van der Lee DI, van der Meijden ED, van Bergen CA, Kester MG, Honders MW, Vermaat M, Eefting M, Marijt EW, Kielbasa SM, Hoen PA, Falkenburg JH, Griffioen M.

Clin Cancer Res. 2016 Aug 15;22(16):4185-96. doi: 10.1158/1078-0432.CCR-15-2307. Epub 2016 Mar 10.

12.

LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application.

Pont MJ, Hobo W, Honders MW, van Luxemburg-Heijs SA, Kester MG, van Oeveren-Rietdijk AM, Schaap N, de Boer HC, van Bergen CA, Dolstra H, Falkenburg JH, Griffioen M.

Haematologica. 2015 Oct;100(10):e419-22. doi: 10.3324/haematol.2015.125021. Epub 2015 Jun 11. No abstract available.

13.

Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.

Hombrink P, Hassan C, Kester MG, Jahn L, Pont MJ, de Ru AH, van Bergen CA, Griffioen M, Falkenburg JH, van Veelen PA, Heemskerk MH.

Clin Cancer Res. 2015 May 1;21(9):2177-86. doi: 10.1158/1078-0432.CCR-14-2188. Epub 2015 Jan 14.

14.

Naturally processed non-canonical HLA-A*02:01 presented peptides.

Hassan C, Chabrol E, Jahn L, Kester MG, de Ru AH, Drijfhout JW, Rossjohn J, Falkenburg JH, Heemskerk MH, Gras S, van Veelen PA.

J Biol Chem. 2015 Jan 30;290(5):2593-603. doi: 10.1074/jbc.M114.607028. Epub 2014 Dec 12.

15.

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.

Jahn L, Hombrink P, Hassan C, Kester MG, van der Steen DM, Hagedoorn RS, Falkenburg JH, van Veelen PA, Heemskerk MH.

Blood. 2015 Feb 5;125(6):949-58. doi: 10.1182/blood-2014-07-587840. Epub 2014 Nov 20.

16.

Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy.

van der Waart AB, van de Weem NM, Maas F, Kramer CS, Kester MG, Falkenburg JH, Schaap N, Jansen JH, van der Voort R, Gattinoni L, Hobo W, Dolstra H.

Blood. 2014 Nov 27;124(23):3490-500. doi: 10.1182/blood-2014-05-578583. Epub 2014 Oct 21.

17.

Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes.

Hassan C, Kester MG, Oudgenoeg G, de Ru AH, Janssen GM, Drijfhout JW, Spaapen RM, Jiménez CR, Heemskerk MH, Falkenburg JH, van Veelen PA.

J Proteomics. 2014 Sep 23;109:240-4. doi: 10.1016/j.jprot.2014.07.009. Epub 2014 Jul 19.

PMID:
25050860
18.

Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.

Lugthart G, van Ostaijen-Ten Dam MM, Jol-van der Zijde CM, van Holten TC, Kester MG, Heemskerk MH, Bredius RG, van Tol MJ, Lankester AC.

Biol Blood Marrow Transplant. 2014 May;20(5):655-61. doi: 10.1016/j.bbmt.2014.01.018. Epub 2014 Jan 23.

19.

Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire.

Hombrink P, Raz Y, Kester MG, de Boer R, Weißbrich B, von dem Borne PA, Busch DH, Schumacher TN, Falkenburg JH, Heemskerk MH.

Eur J Immunol. 2013 Nov;43(11):3038-50. doi: 10.1002/eji.201343397. Epub 2013 Aug 25.

20.

The human leukocyte antigen-presented ligandome of B lymphocytes.

Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, Leunissen JA, Heemskerk MH, Falkenburg JH, van Veelen PA.

Mol Cell Proteomics. 2013 Jul;12(7):1829-43. doi: 10.1074/mcp.M112.024810. Epub 2013 Mar 12.

21.

Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach.

Hombrink P, Hassan C, Kester MG, de Ru AH, van Bergen CA, Nijveen H, Drijfhout JW, Falkenburg JH, Heemskerk MH, van Veelen PA.

J Immunol. 2013 Apr 15;190(8):3869-77. doi: 10.4049/jimmunol.1202351. Epub 2013 Mar 8.

22.

Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice.

Unger WW, Pearson T, Abreu JR, Laban S, van der Slik AR, der Kracht SM, Kester MG, Serreze DV, Shultz LD, Griffioen M, Drijfhout JW, Greiner DL, Roep BO.

PLoS One. 2012;7(11):e49213. doi: 10.1371/journal.pone.0049213. Epub 2012 Nov 14.

23.

Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.

van Luijn MM, van de Loosdrecht AA, Lampen MH, van Veelen PA, Zevenbergen A, Kester MG, de Ru AH, Ossenkoppele GJ, van Hall T, van Ham SM.

PLoS One. 2012;7(4):e34649. doi: 10.1371/journal.pone.0034649. Epub 2012 Apr 26.

24.

Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill β-cells.

Kronenberg D, Knight RR, Estorninho M, Ellis RJ, Kester MG, de Ru A, Eichmann M, Huang GC, Powrie J, Dayan CM, Skowera A, van Veelen PA, Peakman M.

Diabetes. 2012 Jul;61(7):1752-9. doi: 10.2337/db11-1520. Epub 2012 Apr 20.

25.

Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.

Griffioen M, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Lurvink EG, Kester MG, van Bergen CA, Falkenburg JH.

Haematologica. 2012 Aug;97(8):1196-204. doi: 10.3324/haematol.2011.049478. Epub 2012 Mar 14.

26.

A NOVel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals.

Heidt S, Roelen DL, de Vaal YJ, Kester MG, Eijsink C, Thomas S, van Besouw NM, Volk HD, Weimar W, Claas FH, Mulder A.

Am J Transplant. 2012 Jun;12(6):1469-78. doi: 10.1111/j.1600-6143.2011.03982.x. Epub 2012 Mar 5.

27.

Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.

Zandvliet ML, Kester MG, van Liempt E, de Ru AH, van Veelen PA, Griffioen M, Guchelaar HJ, Falkenburg JH, Meij P.

J Immunother. 2012 Feb-Mar;35(2):142-53. doi: 10.1097/CJI.0b013e318243f1ed.

PMID:
22306902
28.

Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.

Lugthart G, Albon SJ, Ricciardelli I, Kester MG, Meij P, Lankester AC, Amrolia PJ.

J Immunother. 2012 Jan;35(1):42-53. doi: 10.1097/CJI.0b013e31823569e2.

PMID:
22130159
29.

Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific.

Amir AL, van der Steen DM, Hagedoorn RS, Kester MG, van Bergen CA, Drijfhout JW, de Ru AH, Falkenburg JH, van Veelen PA, Heemskerk MH.

Blood. 2011 Dec 22;118(26):6733-42. doi: 10.1182/blood-2011-05-354787. Epub 2011 Oct 4.

30.

High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations.

Hombrink P, Hadrup SR, Bakker A, Kester MG, Falkenburg JH, von dem Borne PA, Schumacher TN, Heemskerk MH.

PLoS One. 2011;6(8):e22523. doi: 10.1371/journal.pone.0022523. Epub 2011 Aug 5.

31.

Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity.

Falkenburg WJ, Melenhorst JJ, van de Meent M, Kester MG, Hombrink P, Heemskerk MH, Hagedoorn RS, Gostick E, Price DA, Falkenburg JH, Barrett AJ, Jedema I.

J Immunol. 2011 Sep 1;187(5):2824-33. doi: 10.4049/jimmunol.1100852. Epub 2011 Aug 5.

32.

PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.

Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG, Hebeda K, Falkenburg JH, Schaap N, de Witte TM, van der Voort R, Dolstra H.

Cancer Res. 2011 Aug 1;71(15):5111-22. doi: 10.1158/0008-5472.CAN-11-0108. Epub 2011 Jun 9.

33.

Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers.

Unger WW, Velthuis J, Abreu JR, Laban S, Quinten E, Kester MG, Reker-Hadrup S, Bakker AH, Duinkerken G, Mulder A, Franken KL, Hilbrands R, Keymeulen B, Peakman M, Ossendorp F, Drijfhout JW, Schumacher TN, Roep BO.

J Autoimmun. 2011 Nov;37(3):151-9. doi: 10.1016/j.jaut.2011.05.012. Epub 2011 Jun 1.

PMID:
21636247
34.

Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells.

Jedema I, van de Meent M, Pots J, Kester MG, van der Beek MT, Falkenburg JH.

Haematologica. 2011 Aug;96(8):1204-12. doi: 10.3324/haematol.2010.039099. Epub 2011 May 5.

35.

Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.

Zandvliet ML, van Liempt E, Jedema I, Kruithof S, Kester MG, Guchelaar HJ, Falkenburg JH, Meij P.

J Immunother. 2011 Apr;34(3):307-19. doi: 10.1097/CJI.0b013e318213cb90.

PMID:
21389867
36.

HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands.

Nijveen H, Kester MG, Hassan C, Viars A, de Ru AH, de Jager M, Falkenburg JH, Leunissen JA, van Veelen PA.

Immunogenetics. 2011 Mar;63(3):143-53. doi: 10.1007/s00251-010-0497-1. Epub 2010 Dec 2.

37.

High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning.

Van Bergen CA, Rutten CE, Van Der Meijden ED, Van Luxemburg-Heijs SA, Lurvink EG, Houwing-Duistermaat JJ, Kester MG, Mulder A, Willemze R, Falkenburg JH, Griffioen M.

Cancer Res. 2010 Nov 15;70(22):9073-83. doi: 10.1158/0008-5472.CAN-10-1832. Epub 2010 Nov 9.

38.

Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection.

Zandvliet ML, Falkenburg JH, van Liempt E, Veltrop-Duits LA, Lankester AC, Kalpoe JS, Kester MG, van der Steen DM, van Tol MJ, Willemze R, Guchelaar HJ, Schilham MW, Meij P.

Haematologica. 2010 Nov;95(11):1943-51. doi: 10.3324/haematol.2010.022947. Epub 2010 Jun 18.

39.

Allo-HLA reactivity of virus-specific memory T cells is common.

Amir AL, D'Orsogna LJ, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer R, van der Hoorn MA, Kester MG, Doxiadis II, Falkenburg JH, Claas FH, Heemskerk MH.

Blood. 2010 Apr 15;115(15):3146-57. doi: 10.1182/blood-2009-07-234906. Epub 2010 Feb 16. Erratum in: Blood. 2010 Dec 2;116(23):5079.

40.

Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy.

Griffioen M, van Egmond EH, Kester MG, Willemze R, Falkenburg JH, Heemskerk MH.

Haematologica. 2009 Sep;94(9):1316-20. doi: 10.3324/haematol.2008.001677.

41.

New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire.

D'Orsogna LJ, Amir AL, Zoet YM, van der Meer-Prins PM, van der Slik AR, Kester MG, Heemskerk MH, Doxiadis II, Roelen DL, Claas FH.

Tissue Antigens. 2009 Oct;74(4):290-7. doi: 10.1111/j.1399-0039.2009.01311.x. Epub 2009 Jul 15.

PMID:
19624615
42.

Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells.

Overes IM, Fredrix H, Kester MG, Falkenburg JH, van der Voort R, de Witte TM, Dolstra H.

J Immunother. 2009 Jul-Aug;32(6):539-51. doi: 10.1097/CJI.0b013e3181987c22.

PMID:
19483655
43.

Identification of varicella-zoster virus-specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantation.

van der Heiden PL, de Boer R, van der Steen DM, Kester MG, van der Hoorn MW, Haarman WM, Barnby-Porritt HE, Fry JW, Napper CE, Marijt EW, Willemze R, Falkenburg JH, Heemskerk MH.

J Virol. 2009 Jul;83(14):7361-4. doi: 10.1128/JVI.02662-08. Epub 2009 Apr 22.

44.

Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele.

Spierings E, Gras S, Reiser JB, Mommaas B, Almekinders M, Kester MG, Chouquet A, Le Gorrec M, Drijfhout JW, Ossendorp F, Housset D, Goulmy E.

J Immunol. 2009 Apr 15;182(8):4809-16. doi: 10.4049/jimmunol.0803911.

45.

Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells.

van Loenen MM, Hagedoorn RS, Kester MG, Hoogeboom M, Willemze R, Falkenburg JH, Heemskerk MH.

Cancer Res. 2009 Mar 1;69(5):2034-41. doi: 10.1158/0008-5472.CAN-08-2523. Epub 2009 Feb 17.

46.

Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.

Norde WJ, Overes IM, Maas F, Fredrix H, Vos JC, Kester MG, van der Voort R, Jedema I, Falkenburg JH, Schattenberg AV, de Witte TM, Dolstra H.

Blood. 2009 Mar 5;113(10):2312-23. doi: 10.1182/blood-2008-04-153825. Epub 2008 Dec 12.

47.

Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application.

Griffioen M, van Egmond HM, Barnby-Porritt H, van der Hoorn MA, Hagedoorn RS, Kester MG, Schwabe N, Willemze R, Falkenburg JH, Heemskerk MH.

Haematologica. 2008 Oct;93(10):1535-43. doi: 10.3324/haematol.13067. Epub 2008 Sep 2.

48.

Human clonal CD8 autoreactivity to an IGRP islet epitope shared between mice and men.

Unger WW, Pinkse GG, Mulder-van der Kracht S, van der Slik AR, Kester MG, Ossendorp F, Drijfhout JW, Serreze DV, Roep BO.

Ann N Y Acad Sci. 2007 Apr;1103:192-5. Epub 2007 Mar 21.

PMID:
17376840
49.

Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers.

Oosten LE, Blokland E, Kester MG, Falkenburg JH, van Halteren AG, Goulmy E.

Biol Blood Marrow Transplant. 2007 Feb;13(2):151-63.

50.

Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.

van Bergen CA, Kester MG, Jedema I, Heemskerk MH, van Luxemburg-Heijs SA, Kloosterboer FM, Marijt WA, de Ru AH, Schaafsma MR, Willemze R, van Veelen PA, Falkenburg JH.

Blood. 2007 May 1;109(9):4089-96. Epub 2007 Jan 18.

Supplemental Content

Loading ...
Support Center